Charles Schwab Investment Management leans into AI, healthcare, and quality defensives

The biggest capital re‑deployment is not into the headline AI leaders they already own, but into the enablers and stabilizers of that ecosystem.

Health care is the clear winner. UnitedHealth is up +146.6% in shares, adding about $3.35B and lifting it to 0.86% of the book, while Abbott Labs explodes by +245.0% in shares for a roughly $3.32B increase to 0.71%. These are big, liquid, multi‑product platforms, and Schwab is using them as ballast: diversified payor plus devices/diagnostics rather than doubling down on single‑drug biotech risk.

On the tech side, they treat AI as infrastructure more than narrative. NVIDIA still grows, with shares up +3.1% and an extra $835.6M despite the position already at 4.28%. Qualcomm is the real statement: shares up +365.5%, a ~$3.12B add, moving it to 0.61% and signaling a bet that AI at the edge and wireless complexity are under‑appreciated compared with the megacap GPU story.

Around the edges, Schwab leans into durable cash‑flow machines. Procter & Gamble’s shares jump +120.2%, adding about $3.26B to make it a 0.91% stake. Accenture, despite being in the red versus cost, sees a +259.3% share increase and a ~$2.79B add, and Comcast’s position is up +212.4% in shares, with around $2.37B of fresh capital despite being below their average buy price.

This pattern — aggressively adding to big, steady, slightly out‑of‑favor compounders like Accenture, Comcast, and Blackstone (shares up +390.8%, +$1.96B) — suggests Schwab is deliberately using volatility to scale into quality franchises they already know, even when near‑term performance is uncomfortable.

The sells are not a wholesale de‑risk; they are targeted harvests from mature, slower‑growth franchises and older defensives.

Telecom hardware is the clearest casualty. Cisco’s shares are cut -51.8%, taking out roughly $2.83B of exposure, while Verizon is trimmed -3.1%, freeing another ~$182.4M. That capital largely resurfaces in Qualcomm and Comcast — a rotation from low‑growth, capex‑heavy incumbents to platforms with more optionality on bandwidth and content.

Within health care, Schwab is reshuffling the deck rather than exiting the sector. AbbVie is slashed by -48.5% (about -$2.65B), Bristol‑Myers is down -14.3% (-$619.1M), and Altria — a quasi‑health/consumer name in their classification — is cut -17.2% (-$741.7M). The proceeds line up neatly against the outsized adds in UnitedHealth, Abbott, and Amgen (+8.1%, +$338.6M), moving from concentrated patent and regulatory risk toward diversified platforms and payors.

Defense and energy also provide liquidity. Lockheed Martin is down -17.2%, a ~$898.8M reduction, and ConocoPhillips is trimmed -8.5%, freeing about $467.0M, even as Chevron and Exxon are marginally increased. Schwab is clearly not abandoning the complex, but it is taking profits in some of the more cyclical and politically exposed names.

Even within Schwab’s own ETF sleeves, there is a quiet re‑tilt: FNDF is reduced -2.4% in shares (-$168.9M), while domestic bond ETFs SCHR and SMBS see +4.7% and +5.4% share growth. That hints at using international value and high‑yield exposures as funding for duration and quality credit at the margin.

Look at the sector bars and the story is subtle but deliberate: tech’s headline weight slips from 40.03% to 39.71%, yet the portfolio is now more leveraged to AI and high‑margin compute than before.

Inside technology, they are quietly swapping out low‑growth plumbing for higher‑beta AI infrastructure. Cisco and Verizon shrink, while NVIDIA, Broadcom, Texas Instruments, Qualcomm, AMD, Palantir, and Micron all see share increases. That’s a pivot from legacy networking and wireline telephony toward semis and software tied to data centers, wireless, and AI workloads.

Health care gains from 12.22% to 12.53%, but the internal mix is the real story: out of AbbVie, Bristol‑Myers, and Altria, into UnitedHealth, Abbott, Eli Lilly, and Amgen. It’s a tilt toward diversified therapeutics and payors over single‑asset, patent‑cycle stories. Consumer discretionary steps up from 10.12% to 10.89% as Schwab adds Amazon, Home Depot, Costco, Netflix, and especially Procter & Gamble — essentially buying the parts of consumer spending that can withstand rate volatility.

Finance and the mis‑classified “real estate” bucket both rise — finance from 1.95% to 2.47% via JPMorgan and Blackstone, and “real estate” from 2.61% to 3.36% via Visa, Mastercard, and Accenture. Energy, industrials, and telecom all edge lower, and the unclassified ETF sleeve falls from 14.95% to 14.33%, signaling a slow drift from broad beta toward targeted, single‑name bets.

The result is a book that still tracks the benchmark but leans more heavily into AI, health care scale, and fee‑based cash‑flow machines, with slightly less exposure to hard cyclicals and legacy income names.

Taken together, this quarter reads like a recommitment to a three‑legged stool: AI infrastructure, health care platforms, and quality cash‑flow compounders.

On AI, Schwab is not chasing new tickers; it’s compounding into incumbents. NVIDIA, AMD, Broadcom, and Micron all remain core, and the huge add in Qualcomm suggests a view that connectivity and edge compute will be the next leg of the theme. The modest increases in Alphabet, Meta (despite a small trim in one line), and Amazon underscore a belief that AI value will accrue to platforms with both data and distribution.

In health care, the rotation away from AbbVie, Bristol‑Myers, and Altria and toward UnitedHealth, Abbott, Amgen, Merck, Eli Lilly, and Johnson & Johnson points to a long‑term bet on diversified health‑spend growth rather than narrow drug bets. If health care inflation persists, Schwab wants to own the toll collectors, not just the molecule owners.

The bulking up of Procter & Gamble, Coca‑Cola, PepsiCo, Comcast, Costco, Visa, Mastercard, Accenture, and Blackstone signals a second, quieter thesis: own capital‑light, brand and network‑driven compounders that can pass through costs and monetize volatility. Trims in Lockheed, ConocoPhillips, Cisco, Verizon, and high‑yield tobacco show where they are willing to step back when valuations or policy risk look less compelling.

Going forward, expect this book to keep tilting at the margin: more AI infrastructure than hardware commoditization, more health care scale than binary drug risk, and more fee and brand economics than deep cyclicals — all while staying close enough to the benchmark that these are strong tilts, not outright regime bets.